A new study (the first clinical trial of its kind) has shown that the GLP-1 agonist semaglutide — known by the brand name Ozempic — may help reduce not only alcohol cravings, but the amount of alcohol consumed when someone on the drug does drink

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other conditions with newer weight-loss drugs.

Results showed that people craved and drank less alcohol when on the drug, according to the findings of a recent study.